Korean J Hepatobiliary Pancreat Surg.  2015 Nov;19(4):173-180. 10.14701/kjhbps.2015.19.4.173.

Comparative analysis of intraoperative radiofrequency ablation versus non-anatomical hepatic resection for small hepatocellular carcinoma: short-term result

Affiliations
  • 1Department of surgery, Chungnam National University Hospital, Daejeon, Korea. oxali@hanmail.net

Abstract

BACKGROUNDS/AIMS
To compare the clinical outcomes of intraoperative radiofrequency ablation (RFA) and non-anatomical hepatic resection (NAHR) for small hepatocellular carcinoma (HCC).
METHODS
From February 2007 to January 2015, clinical outcomes of thirty four patients with HCC receiving RFA or NAHR were compared, retrospectively.
RESULTS
There was no difference of patient and tumor characteristic between the two groups that received RFA or NAHR. The 1, 2, and 3-year recurrence rates following RFA were 32.2%, 32.2% and 59.3% respectively, and 6.7%, 33.3% and 33.3% following NAHR respectively (p=0.287). The 1, 2 and 3-year overall survival (OS) rates following RFA were 100%, 88.9% and 76.2% respectively, and 100%, 85.6% and 85.6%, respectively, following NAHR (p=0.869). We did not find a definite statistical difference in recurrence rate and OS rate between the two groups. In the multivariate analysis, number of tumor was an independent prognostic factor for recurrence and albumin was an independent prognostic factor for OS.
CONCLUSIONS
We recommend non-anatomical hepatic resection rather than intraoperative RFA in small sized HCC, due to a higher recurrence rate in intraoperative RFA. Intraoperative RFA was inferior to non-anatomical hepatic resection in terms of recurrence rate. We need to select the optimal treatment considering liver function and possibility of recurrence.

Keyword

Hepatocellular carcinoma; Radiofrequency ablation; Liver resection

MeSH Terms

Carcinoma, Hepatocellular*
Catheter Ablation*
Humans
Liver
Multivariate Analysis
Recurrence
Retrospective Studies

Figure

  • Fig. 1 Patient selection process.

  • Fig. 2 Comparison of the recurrence rates after propensity matching analysis.

  • Fig. 3 Comparison of the overall survival rates after propensity matching analysis.


Reference

1. Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transpl Surg. 1998; 4(5 Suppl 1):S87–S91. PMID: 9742499.
2. European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908–943. PMID: 22424438.
3. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020–1022. PMID: 21374666.
Article
4. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014; 9:e84484. PMID: 24404166.
Article
5. Makuuchi M, Imamura H, Sugawara Y, Takayama T. Progress in surgical treatment of hepatocellular carcinoma. Oncology. 2002; 62(Suppl 1):74–81. PMID: 11868790.
Article
6. Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009; 115:571–580. PMID: 19117347.
Article
7. Marubashi S, Gotoh K, Akita H, Takahashi H, Ito Y, Yano M, et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg. 2015; 102:776–784. PMID: 25847111.
Article
8. Tomimaru Y, Eguchi H, Marubashi S, Wada H, Kobayashi S, Tanemura M, et al. Equivalent outcomes after anatomical and non-anatomical resection of small hepatocellular carcinoma in patients with preserved liver function. Dig Dis Sci. 2012; 57:1942–1948. PMID: 22407377.
Article
9. Yun D, Kim S, Song I, Chun K. Comparative analysis of Laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors. Korean J Hepatobiliary Pancreat Surg. 2014; 18:122–128. PMID: 26155264.
Article
10. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008; 47:82–89. PMID: 18008357.
Article
11. Majno PE, Mentha G, Mazzaferro V. Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection. Hepatology. 2010; 51:1116–1118. PMID: 20373366.
Article
12. Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl. 2004; 10(2 Suppl 1):S98–S106. PMID: 14762848.
Article
13. Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008; 15:972–978. PMID: 18236118.
Article
14. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010; 116:3638–3644. PMID: 20564097.
15. Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010; 20:130–140. PMID: 20551807.
Article
16. Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013; 43:853–864. PMID: 23281579.
17. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012; 56:412–418. PMID: 21756858.
Article
18. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology. 2000; 32:1216–1223. PMID: 11093727.
Article
19. Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007; 17:684–692. PMID: 17093964.
Article
20. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008; 207:20–29. PMID: 18589357.
Article
21. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 234:961–967. PMID: 15665226.
Article
22. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005; 103:1201–1209. PMID: 15690326.
23. Guglielmi A, Ruzzenente A, Battocchia A, Tonon A, Fracastoro G, Cordiano C. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology. 2003; 50:480–484. PMID: 12749252.
24. Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005; 12:616–628. PMID: 15965731.
Article
25. Xu HX, Lu MD, Xie XY, Yin XY, Kuang M, Chen JW, et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol. 2005; 60:1018–1025. PMID: 16124984.
Article
26. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50:1475–1483. PMID: 19731239.
27. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004; 240:900–909. PMID: 15492574.
28. Iida H, Aihara T, Ikuta S, Yamanaka N. Effectiveness of impedance monitoring during radiofrequency ablation for predicting popping. World J Gastroenterol. 2012; 18:5870–5878. PMID: 23139602.
Article
29. Tanaka K, Shimada H, Matsumoto C, Matsuo K, Nagano Y, Endo I, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery. 2008; 143:607–615. PMID: 18436008.
Article
30. Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg. 2014; 18:1994–2002. PMID: 25213582.
31. Goh BK, Chow PK, Teo JY, Wong JS, Chan CY, Cheow PC, et al. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg. 2014; 18:1477–1485. PMID: 24855028.
Article
32. Kang SH, Kim DY, Jeon SM, Ahn SH, Park JY, Kim SU, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol. 2012; 24:849–856. PMID: 22495400.
Article
Full Text Links
  • KJHBPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr